Floatz logo

TACROLIMUS

Blastic Plasmacytoid Dendritic Cell Neoplasm

Fred Hutchinson Cancer CenterSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Blastic Plasmacytoid Dendritic Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Tagraxofusp
French Innovative Leukemia Organisation
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB
Fludarabine
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B

View all 48 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →